Adjunct Therapies to Standard Care for IBS and IBD Patients: Digestive Symptoms Improvement and Quality of Life Optimization
- PMID: 39599713
- PMCID: PMC11597149
- DOI: 10.3390/nu16223927
Adjunct Therapies to Standard Care for IBS and IBD Patients: Digestive Symptoms Improvement and Quality of Life Optimization
Abstract
Background: The prevalence of both inflammatory bowel diseases (IBD) and Irritable Bowel Syndrome (IBS) is increasing, with persistent digestive symptoms, an altered quality of life, and higher rates of anxiety, chronic fatigue, and sleep trouble than the general population. Methods: This scoping review will analyze the latest clinical practice recommendations and clinical studies on non-pharmaceutical interventions such as diet adaptations, physical activity, cognitive behavioral therapies, and medical nutrition therapies such as probiotics, soluble fibers, chitin-glucan, and micronutrients for digestive symptoms relief, quality of life improvement and nutritional deficiencies correction in IBS and IBD patients. The objective is to help healthcare practitioners and dietitians to build personalized care program for IBD and IBS patients. Results: Mediterranean diet, physical activity, cognitive behavioral therapies and medical nutrition therapies such as selected probiotics, soluble fibers, chitin glucan, peppermint oil and micronutrients are effective as adjunct therapies. Conclusions: These adjunct therapies may help to reduce persistent digestive symptoms, correct nutritional deficiencies and improve quality of life of IBS and IBD patients.
Keywords: Mediterranean diet; fibers; inflammatory bowel disease; irritable bowel syndrome; medical nutrition therapies; physical activity; probiotics.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.Gastroenterology. 2024 Mar;166(3):521-532. doi: 10.1053/j.gastro.2023.11.303. Epub 2024 Jan 23. Gastroenterology. 2024. PMID: 38276922
-
Efficacy of a Digital Personalized Elimination Diet for the Self-Management of Irritable Bowel Syndrome and Comorbid Irritable Bowel Syndrome and Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2023 Jan 1;14(1):e00545. doi: 10.14309/ctg.0000000000000545. Clin Transl Gastroenterol. 2023. PMID: 36322404 Free PMC article.
-
Nutrition and inflammatory bowel disease: primary or adjuvant therapy.Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):491-6. doi: 10.1097/MCO.0b013e328349eb4d. Curr Opin Clin Nutr Metab Care. 2011. PMID: 21832904 Review.
-
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):102-107. Eur Rev Med Pharmacol Sci. 2017. PMID: 28724171 Clinical Trial.
-
Diet, fibers, and probiotics for irritable bowel syndrome.J Med Life. 2022 Feb;15(2):174-179. doi: 10.25122/jml-2022-0028. J Med Life. 2022. PMID: 35419092 Free PMC article. Review.
References
-
- Alatab S., Sepanlou S., Ikuta K., Vahedi H., Bisignano C., Safiri S., Sadeghi A., Nixon M., Abdoli A., Abolhassani H., et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;5:17–30. doi: 10.1016/S2468-1253(19)30333-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources